title: Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.
abstract: A 53-year-old male with myelodysplastic syndrome developed Sweet's syndrome extensively over his left iliac and inguinal regions that was refractory to standard treatment with corticosteroids and chemotherapy, received a stem cell transplant from an HLA-matched unrelated donor, conditioned by reduced-intensity regimen. The patient achieved complete hematological remission, and the cutaneous lesions improved gradually and then disappeared completely despite the patient receiving granulocyte colony-stimulating factor after transplantation and developing acute graft-versus-host disease.
authors.affiliation: Division of Hematology, Department of Internal Medicine, Kinki University School of Medicine, 377-2, Ohonohigashi, Osakasayama, Osaka, Japan. ashida@med.kindai.ac.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Ashida
authors.forename: Takashi
authors.initials: T
authors.lastname: Mayama
authors.forename: Masaki
authors.initials: M
authors.lastname: Higashishiba
authors.forename: Kazunobu
authors.initials: K
authors.lastname: Kawanishi
authors.forename: Junichi
authors.initials: J
authors.lastname: Miyatake
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Tatsumi
authors.forename: Akihisa
authors.initials: A
authors.lastname: Kanamaru
mesh_terms: D015250:Aclarubicin / Q000627:therapeutic use; D000754:Anemia, Refractory, with Excess of Blasts / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002066:Busulfan / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction; D016463:Sweet Syndrome / Q000188:drug therapy / Q000209:etiology*; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000009:adverse effects; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D003561:Cytarabine; D015250:Aclarubicin; D011239:Prednisolone; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine